Ista Aims To Position Xibrom Using Phase III Dosing, Side Effect Profile; Plans 60-Rep Sales Force
This article was originally published in The Pink Sheet Daily
Executive Summary
The bromfenac ophthalmic formulation did not show evidence of the liver toxicity that caused oral bromfenac (Wyeth’s Duract) to be withdrawn. Ista plans a second quarter NDA filing to treat ocular inflammation post-cataract surgery.
You may also be interested in...
Ista Submits Xibrom NDA For Ocular Inflammation
Ista has submitted an NDA for Xibrom (bromfenac, .1%) for treatment of ocular inflammation following cataract surgery, the firm announced May 25
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.